Part D Plans’ Single Source Drug Negotiations Yielding “Significant” Savings, BIO Analysis Concludes
This article was originally published in The Pink Sheet Daily
Executive Summary
Medicare Part D drug plan sponsors are negotiating “significant” discounts for single source brand drugs, the Biotechnology Industry Organization asserts in a report issued Feb. 26.